A detailed history of China Universal Asset Management Co., Ltd. transactions in Morphic Holding, Inc. stock. As of the latest transaction made, China Universal Asset Management Co., Ltd. holds 9,630 shares of MORF stock, worth $328,094. This represents 0.04% of its overall portfolio holdings.

Number of Shares
9,630
Previous 9,630 -0.0%
Holding current value
$328,094
Previous $339,000 0.29%
% of portfolio
0.04%
Previous 0.04%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 29, 2024

BUY
$26.64 - $40.31 $103,283 - $156,281
3,877 Added 67.39%
9,630 $339,000
Q4 2023

May 21, 2024

SELL
$19.95 - $31.0 $77,346 - $120,187
-3,877 Reduced 40.26%
5,753 $166,000
Q4 2023

Jan 23, 2024

BUY
$19.95 - $31.0 $90,074 - $139,965
4,515 Added 364.7%
5,753 $166,000
Q3 2023

May 21, 2024

BUY
$21.33 - $59.42 $13,608 - $37,909
638 Added 106.33%
1,238 $28,000
Q3 2023

Oct 30, 2023

BUY
$21.33 - $59.42 $13,608 - $37,909
638 Added 106.33%
1,238 $28,000
Q2 2023

May 21, 2024

BUY
$34.33 - $62.11 $2,197 - $3,975
64 Added 11.94%
600 $34,000
Q2 2023

Jul 27, 2023

BUY
$34.33 - $62.11 $2,197 - $3,975
64 Added 11.94%
600 $34,000
Q1 2023

May 21, 2024

BUY
$26.01 - $48.69 $3,745 - $7,011
144 Added 36.73%
536 $20,000
Q1 2023

Apr 27, 2023

BUY
$26.01 - $48.69 $3,745 - $7,011
144 Added 36.73%
536 $20,000
Q4 2022

May 21, 2024

SELL
$24.14 - $30.37 $223,005 - $280,558
-9,238 Reduced 95.93%
392 $10,000
Q4 2022

Jan 31, 2023

BUY
$24.14 - $30.37 $772 - $971
32 Added 8.89%
392 $10,000
Q3 2022

Oct 21, 2022

BUY
$22.23 - $33.37 $8,002 - $12,013
360 New
360 $10,000

Others Institutions Holding MORF

About Morphic Holding, Inc.


  • Ticker MORF
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,477,100
  • Market Cap $1.31B
  • Description
  • Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical ...
More about MORF
Track This Portfolio

Track China Universal Asset Management Co., Ltd. Portfolio

Follow China Universal Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.